Clostridium difficile in inflammatory bowel disease
- Authors: Knyazev OV1, Kagramanova AV1, Chernova ME1, Korneeva IA1, Parfenov AI1
-
Affiliations:
- A.S. Loginov Moscow Clinical Scientific Center
- Issue: Vol 90, No 11 (2018)
- Pages: 32-36
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32863
- DOI: https://doi.org/10.26442/terarkh201890114-36
- ID: 32863
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
O V Knyazev
A.S. Loginov Moscow Clinical Scientific Centerд.м.н., зав. отд-нием воспалительных заболеваний кишечника Moscow, Russia
A V Kagramanova
A.S. Loginov Moscow Clinical Scientific Centerк.м.н., с.н.с. отд-ния патологии кишечника Moscow, Russia
M E Chernova
A.S. Loginov Moscow Clinical Scientific Centerк.м.н., врач-инфекционист Moscow, Russia
I A Korneeva
A.S. Loginov Moscow Clinical Scientific Centerврач-гастроэнтеролог отд-ния воспалительных заболеваний кишечника Moscow, Russia
A I Parfenov
A.S. Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
д.м.н., проф., зав. отд. патологии кишечника ГБУЗ МКНЦ им. А.С. Логинова ДЗМ Moscow, Russia
References
- Magill S.S, Edwards J.R, Bamberg W, et al. Multistate point - prevalence survey of health care associated infections. New Eng J Med. 2014;370:1198-208.
- Salen P, Stankewicz H.A. Colitis, Pseudomembranous. StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2018 Jan-2017 Dec 4.
- Tariq R, Singh S, Gupta A, Pardi D.S, Khanna S. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta - analysis. JAMA Intern Med. 2017(Jun1);177(6):784-91. doi: 10.1001/jamainternmed.2017.0212
- Lessa F.C, Mu Y, Bamberg W.M, et al. Burden of Clostridium difficile infection in the United States. New Eng J Med. 2015;372(9):825-34.
- Miller B.A, Chen L.F, Sexton D.J, Anderson D.J. Comparison of the burdens of hospital - onset, healthcare facility - associated Clostridium difficile infection and of healthcare - associated infection due to methicillin - resistant Staphylococcus aureus in community hospitals. Infection Control and Hospital Epidemiology. 2011;32(4):387-90.
- Zimlichman E, Henderson D, Tamir O, et al. Health care associated infections: a meta - analysis of costs and financial impact on the US health care system. JAMA Int Med. 2013;173(22):2039-46.
- Bignardi G.E. Risk factors for Clostridium difficile infection. J Hosp Inf. 1998;40(1):1-15.
- Khannaand S, Pardi D.S. IBD:poor out comes after Clostridium difficile infection in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(6):307-8.
- Ananthakrishnan A.N, Mc Ginley E.L, Binion D.G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205-10.
- Ananthakrishnan A.N, Oxford E.C, Nguyen D.D, Sauk J, Yajnik V, Xavier RJ. Disclosures Genetic Risk Factors for Clostridium difficile Infection in Ulcerative Colitis. Aliment Pharmacol Ther. 2013;38(5):522-30.
- Khanna S, Pardi D.S. The growing incidence and severity of Clostridium difficile infectionin inpatient and outpatient settings. Exp Rev Gastroenterol Hepatol. 2010;4(4):409-16.
- Khanna S, Pardi D.S, Aronson S.L, et al. The epidemiology of community - acquired Clostridium difficile infection: a population - based study. Am J Gastroenterol. 2012;107(1):89-95.
- Cohen S.H, Gerding D.N, Johnsonetal S. Clinicalpractice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Health care Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology. 2010;31(5):431-55.
- Nguyen G.C, Kaplan G.G, Harris N.L, Brant S.R. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443-50.
- Issa M, Vijayapal A, Graham M.B, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345-51.
- Soler P, Nogareda F, Cano R. Rates of Clostridium difficile infection in patients discharged from Spanish hospitals, 1997-2005. Infection Control and Hospital Epidemiology. 2008;29(9):887-9.
- Burckhardt F, Friedrich A, Beier D, Eckmanns T. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis. 2008;14:691-92.
- Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009: statistical brief №124, in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, Agency for Healthcare Research and Quality (US), Rockville (MD), 2006.
- Reveles K.R, Lee G.C, Boyd N.K, Frei C.R. Therisein Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010. Am J Infect Control. 2014;42(10):1028-32.
- Wilcox M.H, Shetty N, Fawley W.N, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping - based surveillance scheme in England. Clin Infect Dis. 2012;55(8):1056-63.
- Wilcox M.H, Mooney L, Bendall R, Settle C.D, Fawley W.N. A case - control study of community - associated Clostridium difficile infection. J Antimicrob Chemother. 2008;62(2):388-96.
- Kutty P.K, Woods C.W, Sena A.C, et al. Risk factors for and estimated incidence of community - associated Clostridium difficile infection, North Carolina, USA. Emerging Infectious Diseases. 2010;16:197-204.
- Lambert P.J, Dyck M, Thompson L.H, Hammond G.W. Population - based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infection Control and Hospital Epidemiology. 2009;30(10):945-51.
- Issa M, Ananthakrishnan A.N, Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflammat Bowel Diseases. 2008;14(10):1432-42.
- Das R, Feuerstadt P, Brandt L.J. Glucocorticoids are associated with increased risk of short - term mortality in hospitalized patients with clostridium difficile - associated disease. Am J Gastroenterol. 2010;105(9):2040-9.
- Khanna S, Tosh P.K. A clinician’s primer on the role of the microbiome in human health and disease. Mayo Clinic Proceedings. 2014;89(1):107-14.
- Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Seminars in Immunopathology. 2015;37(1):47-55.
- Schneeweiss S, Korzenik J, Solomon D.H, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Alimentary Pharmacol Therapeutics. 2009;30(3):253-64.
- Kariv R, Navaneethan U, Venkatesh P.G, Lopez R, Shen B. Impact of Clostridium difficile infection in patients with ulcerative colitis. J Crohn's & Colitis. 2011;5(1):34-40.
- Engel M.A, Neurath M.F. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010;45(6):571-83.
- Князев О.В., Парфенов А.И., Ручкина И.Н., Лазебник Л.Б., Сагынбаева В.Э. Иммунный ответ на биологическую терапию воспалительных заболеваний кишечника. Терапевтический архив. 2013;85(12):55-9.
- William Gillespie, Neil Marya, Julien Fahed, Gregory Leslie, Krunal Patel, David R. Cave. Clostridium difficile in Inflammatory Bowel Disease: A Retrospective Study. Gastroenterology Research and Practice Volume. 2017; Article ID 4803262:5. https://doi.org/10.1155/ 2017/4803262.
![](/img/style/loading.gif)